This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) (SMAT)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2012 by Heidrun Rexer, Association of Urogenital Oncology (AUO).
Recruitment status was:  Recruiting
University Hospital, Essen
Information provided by (Responsible Party):
Heidrun Rexer, Association of Urogenital Oncology (AUO) Identifier:
First received: October 6, 2010
Last updated: February 10, 2012
Last verified: February 2012
The aim ist to identify biomarkers in the blood, to indicate early response or early treatment resistance.

Condition Intervention Phase
Renal Cell Carcinoma Pulmonary Metastases Drug: Sunitinib Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Prospektiv Randomisierte Multizentrische Phase II-Studie Zur Metastasenresektion Von Lungenfiliae (Poor-prognosis) Beim Klarzelligen Nierenzellkarzinom +/- Adjuvante Sunitinibtherapie über 1 Jahr SMAT - AN 20/04 Der AUO

Resource links provided by NLM:

Further study details as provided by Heidrun Rexer, Association of Urogenital Oncology (AUO):

Primary Outcome Measures:
  • 2 year relapse-free survival [ Time Frame: 5 years ]

Secondary Outcome Measures:
  • perioperative mortality and morbidity [ Time Frame: 5 years ]
  • Side effect of adjuvant therapy [ Time Frame: 5 years ]
  • Quality of Life of the Patient [ Time Frame: 5 years ]
  • Overall Survival [ Time Frame: 5 years ]

Estimated Enrollment: 60
Study Start Date: October 2010
Estimated Study Completion Date: October 2015
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Sunitinib
one year adjuvant treatment with sunitinib
Drug: Sunitinib
one-year adjuvant Treatment with Sunitinib, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break
Other Name: adjuvant Treatment
Placebo Comparator: Placebo
one year treatment with placebo
Drug: Placebo
one-year Treatment, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break,
Other Name: Plazebo

Detailed Description:
Prospective randomized multi-center Phase II trial for resection of metastases from pulmonary metastases (poor prognosis) in clear cell renal cell carcinoma + / - adjuvant sunitinib therapy over one year

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • >/= 2 synchronous or within 24 Months after Nephrectomy occured pulmonary metastases. Patients in whom more back than 2 years of a solitary lung metastasis, bone metastasis or brain metastasis was resected, may also be included in the study.
  • Aged 18 to 75 years
  • functionally acceptable surgical risk
  • Women in conceptional age: negative pregnancy test and adequate contraception
  • Adequate hematologic, renal, hepatic and coagulation-physiological functions
  • Amylase/ Lipase < 1,5 x upper limit of normal
  • Informing the patient about the study and the present written consent to participate after clarification in accordance with the stipulations of AMG(german drug law), and the principles of GCP ("informed consent")
  • Patient compliance and geographic proximity to allow adequate follow-up

Exclusion Criteria:

  • Presence of other metastases outside the lung
  • progress in the 12-week sunitinib therapy before resection of metastases
  • R1 or R2-finding in resection of metastases
  • Dialysis after nephrectomy
  • Previous or existing serious cardiovascular (grade III - IV according to NYHA(New York Heart Association)) disease, active angina pectoris or ischemia, myocardial infarction within previous 6 months , uncontrolled hypertension(RR diastolic 120 mmHg(Millimeters of mercury))
  • serious hematopoetic (e.g. serious Bone marrow aplasia), pulmonary, hepatic or renal Disease
  • Stroke within the previous six months
  • Patients with poorly controlled diabetes mellitus
  • Serious bacterial or fungal infections
  • chronic hepatitis B or C, HIV(human immunodeficiency virus) infection
  • autoimmune disease
  • prior organ transplantation
  • prior autologous bone marrow transplant or stem cell transferred within the last 4 months before study
  • Neuropsychiatric diseases that affect patient compliance
  • Manifesto, second malignancy or other malignancy within the past 5 years (except basal cell carcinoma, carcinoma in situ of the cervix, incidental prostate carcinoma, superficial urothelial Ca pTaG1-2 and pT1G1)
  • Therapy with immunotherapeutic agents including monoclonal antibodies, cytotoxic drugs or hormones (other than bisphosphonates and oral contraceptives) within the last 4 weeks prior to enrollment. Previous use of inhibitors of Ras/Raf-, MEK kinase, AKT kinase and mTOR inhibitors or induction of Farnesyltransferase
  • Previous use of angiogenesis inhibitors such as VEGF / VEGFR, PDGF / PDGFR and other key molecules of angiogenesis
  • parallel treatment with rifampicin
  • Participation in other treatment studies in the last 4 weeks
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01216371

Contact: Susanne Krege, Priv. Doz. Dr. med. 02 151 / 334-23 81

Universitätsmedizin Charité Berlin Not yet recruiting
Berlin, Germany, 10117
Contact: Steffen Weikert, Priv. Doz. Dr. med.    030/84 45-40 84      
Principal Investigator: Steffen Weikert, Priv. Doz. Dr. med.         
Sub-Investigator: Kempkensteffen Carsten, Dr. med.         
Sub-Investigator: Jonas Busch, Dr. med.         
Sub-Investigator: Jan Gregor, Dr. med.         
Sub-Investigator: Jens Neudecker, Dr. med.         
Sub-Investigator: Jens C. Rückert, Dr. med.         
Sub-Investigator: Gertrud Feldmann         
Franziskus Krankenhaus Not yet recruiting
Berlin, Germany, 10787
Contact: Jörg Neymeyer, Dr. med.    030/26 38-38 01      
Principal Investigator: Jörg Neymeyer, Dr. med.         
Sub-Investigator: Thomas Wülfing, Dr. med.         
Helios Klinikum Emil von Behring Not yet recruiting
Berlin, Germany, 14165
Contact: Kollmeier Jens, Dr. med.    030/81 02-14 47      
Sub-Investigator: Jens Kollmeier, Dr. med.         
Sub-Investigator: Bettina Schlolaut, Dr. med.         
university hospital of Düsseldorf Recruiting
Düsseldorf, Germany, 40255
Contact: Peter Albers, Prof. Dr. med.    0211/811-81 10      
Principal Investigator: Peter Albers, Prof. Dr. med.         
Sub-Investigator: Jasper Decoene         
Sub-Investigator: Zenginli Hakan         
Sub-Investigator: Claus F. Eisenberger, Prof. Dr. med.         
Sub-Investigator: Wolfram T. Knoefel, Prof. Dr. med.         
Sub-Investigator: Almut Diem         
university hospital of Essen Recruiting
Essen, Germany, 45122
Contact: Herbert Rübben, Prof. Dr. med.    0201/723-32 10      
Principal Investigator: Herbert Rübben, Prof. Dr. med.         
Sub-Investigator: Marcus Schenk, Dr. med.         
Sub-Investigator: Farnk vom Dorp, Dr. med.         
Sub-Investigator: Min Ju, Dr. med.         
Sub-Investigator: Stephan Tschirdewahn         
Sub-Investigator: Michaela Löbert         
Ruhrlandklinik Department of Thoracic Surgery Not yet recruiting
Essen, Germany, 45239
Contact: Christiane Zimmermann    0201/433-43 24      
Sub-Investigator: Georgios Stamatis, Prof. Dr. med.         
Sub-Investigator: Stefan Welter, Dr. med.         
Sub-Investigator: Silvia Fechner, Dipl. med.         
university hospital of Freiburg Recruiting
Freiburg, Germany, 79106
Contact: Ulrich Wetterauer, Prof. Dr. med.    0761/270-2891      
Principal Investigator: Ulrich Wetterauer, Prof. Dr. med.         
Sub-Investigator: Christian Leiber, Dr. med.         
Sub-Investigator: Christian Stremmel, Prof. Dr. med.         
Sub-Investigator: Jutta Günter, Dr. med.         
university Hospital of Heidelberg Recruiting
Heidelberg, Germany, 69119
Contact: Markus Hohenfellner, Prof. Dr. med.    06221/56-63 21      
Principal Investigator: Markus Hohenfellner, Prof. Dr. med.         
Sub-Investigator: Pahernick Sascha, Priv. Doz. Dr. med.         
Sub-Investigator: Gencay Hatiboglu, Dr. med.         
Sub-Investigator: Johannes Huber, Dr. Dr. med.         
Sub-Investigator: Joachim Pfannschmidt, Priv. Doz. Dr. med.         
Sub-Investigator: Hendrik Dienemann, Prof. Dr. med.         
urological hospital of Maria Hilf Krankenhaus Krefeld Recruiting
Krefeld, Germany, 47805
Contact: Susanne Krege, Priv. Doz. Dr. med.    02151/334-52 74      
Principal Investigator: Susanne Krege, Priv. Doz. Dr. med.         
Sub-Investigator: Florian Hartmann, Dr. med.         
Hospital of Großhadern Not yet recruiting
München, Germany, 81377
Contact: Michael Staehler, Dr. med.    089/70 95-0      
Principal Investigator: Michael Staehler, Dr. med.         
Sub-Investigator: Cordula Nordhaus, Dr. med.         
Sub-Investigator: Philipp Nuhn, Dr. med.         
Sub-Investigator: Hauke Winter, Priv. Doz. Dr. med.         
Sub-Investigator: Rudolf Hatz, Prof. Dr. med.         
Sub-Investigator: Sylvia Dondl         
Dr.-Horst-Schmidt-Kliniken GmbH Recruiting
Wiesbaden, Germany, 65199
Contact: Norbert Frickhofen, Prof. Dr. med.    0611/43-30 09      
Principal Investigator: Norbert Frickhofen, Prof. Dr. med.         
Sub-Investigator: Bernd Jung, Dr. med.         
Sub-Investigator: Heinz G. Fuhr, Dr. med.         
Sub-Investigator: Joachim Schirren, Prof. Dr. med.         
Sub-Investigator: Servet Bölükbas, Dr. med.         
Sub-Investigator: Sabine Labenz         
Sub-Investigator: Birgit Wilde         
Sub-Investigator: Klaudia Fischbach         
Sponsors and Collaborators
Association of Urogenital Oncology (AUO)
University Hospital, Essen
Principal Investigator: Susanne Krege, Priv. Doz. Dr. med. urological hospital of Maria Hilf Krankenhaus Krefeld
  More Information

Responsible Party: Heidrun Rexer, Priv. Doz. Dr. med. Susanne Krege, urological hospital of Maria Hilf Krankenhaus Krefeld, Association of Urogenital Oncology (AUO) Identifier: NCT01216371     History of Changes
Other Study ID Numbers: AN 20/04
2008-007609-36 ( EudraCT Number )
Study First Received: October 6, 2010
Last Updated: February 10, 2012

Keywords provided by Heidrun Rexer, Association of Urogenital Oncology (AUO):

Additional relevant MeSH terms:
Neoplasm Metastasis
Carcinoma, Renal Cell
Lung Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplastic Processes
Pathologic Processes
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors processed this record on June 23, 2017